{'fraction_non_alphanumeric': 0.037783375314861464, 'fraction_numerical': 0.007556675062972292, 'mean_word_length': 5.25984251968504, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[A case of adenocarcinoma of the lung with superior vena cava syndrome (SVCS), effectively treated with implantation of intravascular stent and chemotherapy of single agent of docetaxel].

The patient was a 54-year-old woman with adenocarcinoma of the lung (T2N3M1, Stage IV). Although 3 cycles of a combination of gemcitabine (GEM) with vinorelbine (VNR) and one cycle of carboplatin (CBDCA) with weekly paclitaxel (TXL) were administered, the tumor continued to grow with symptomatic progression of superior vena cava syndrome (SVCS). Implantation of an intravascular metallic stent and chemotherapy with the single agent of docetaxel (TXT) were performed. The tumor regressed and symptomatic improvement was achieved. TXT seems to be a promising drug as a second-line chemotherapy for NSCLC.